Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: A retrospective study by AGEO Emeric Boisteau, Alice Boilève, David Tougeron, Dewi Vernerey, Alice De Malet, Thierry Lecomte, Thomas Aparicio, Simon Pernot, Julien Pinot, Anna Pellat, Vincent Hautefeuille, Nadim Farès, Romain Desgrippes, Romain Coriat, Aziz Zaanan, Julien Edeline, Sara Philonenko, Olivier Dubreuil, Julie Henriques, Anthony Turpin European Journal of Cancer, 2026 BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare malignancy with poor prognosis. In metastatic disease, evidence regarding the efficacy of chemotherapy (CT) combined with bevacizumab or anti-EGFR agents is limited to small studies. This study aimed to assess, in real-world practice, the effectiveness of first-line CT combined with targeted therapies (TT)-either antiangiogenic (AA) or anti-EGFR-compared with CT alone in patients with metastatic SBA (mSBA) and proficient mismatch repair/microsatellite stable (pMMR/MSS) status. PATIENTS AND METHODS: This retrospective multicentre study included all patients receiving at least one cycle of CT with or without TT for mSBA. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and safety. Analyses used inverse probability of treatment weighting (IPTW) in univariable Cox models to account for potential confounding factors that were unbalanced between groups. RESULTS: A total of 255 patients were included: 153 received CT alone, 45 CT+AA, and 16 CT+anti-EGFR as first-line therapy. Median PFS was 8.0 months with CT alone versus 11.9 months with CT+AA (IPTW HR=0.38; 95% CI: 0.29-0.49; p < 0.0001). Median OS was 15.9 versus 23.1 months (IPTW HR=0.38; 95% CI: 0.28-0.51; p < 0.0001). ORR did not differ significantly (33.8% vs 43.2%; p = 0.26). Among 78 patients with RAS wild-type tumours, outcomes did not significantly differ between CT alone and CT+anti-EGFR groups. CONCLUSION: Adding antiangiogenic therapy to CT significantly improved PFS and OS in first-line treatment of mSBA, warranting confirmation through prospective randomized trials.
Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis Sefora Conti, Natalia S. Tissera, Florian Castet, Míriam Basagaña-Farrés, María Teresa Salcedo, Elizabeth Pando, Cristina Dopazo, Lorenzo Caritá, Anthony Turpin, Víctor Navarro Garcés, Guillermo Villacampa, Teresa Macarulla, Tian V. Tian Jhep Reports, 2026 BACKGROUND & AIMS: Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. METHODS: A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). RESULTS: = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. CONCLUSIONS: PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. IMPACT AND IMPLICATIONS: This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma.
Clinical and molecular characteristics of early-onset pancreatic and biliary cancers C. Smolenschi, M. Rémond, M. Valéry, M. Brugel, M. Ducreux, A. Turpin, A. Boilève ESMO Gastrointestinal Oncology, 2026 Biliary tract cancer and pancreatic cancer are aggressive malignancies, typically diagnosed in patients >50 years of age. Lately, <50 years of age has been rising, presenting unique challenges and clinical features that distinguish them from late-onset cases. Here, we review the clinical, biological, and molecular characteristics of early-onset biliary tract cancer and pancreatic cancer and compare them with their late-onset counterparts. We also examine treatment patterns, efficacy, and the potential role of targeted therapies, as well as the potential psychological and social effects on younger patients, with particular emphasis on fertility. We therefore offer insights into the unique challenges and therapeutic strategies in managing early-onset disease.
The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer Carl-Stephan Leonhardt, Mustapha Adham, Shouki Bazarbashi, Irit Ben-Aharon, Regina G H Beets-Tan, Ugo Boggi, Thomas B Brunner, Francesco Cellini, Arturo Chiti, Lois Daamen, Berardino De Bari, Sara De Dosso, Michel Ducreux, Cathy Eng, Massimo Falconi, Cristina R Ferrone, Isabella Frigerio, Ingrid Garajova, Sabine Gerum, Michael Ghadimi, Thomas Gruenberger, Pascal Hammel, Karin Haustermans, Maria Hawkins, Jin He, Hanne D Heerkens, Florence Huguet, Martijn P W Intven, Ulla Klaiber, Tiuri E Kroese, Pierre Laurent-Puig, Florian Lordick, Ethan B Ludmir, Teresa Macarulla, Oscar Matzinger, Alessio G Morganti, Somnath Mukherjee, Eileen M O’Reilly, Joon Oh Park, Demetris Papamichael, Per Pfeiffer, José M Ramia, Falk Roeder, Erika Ruiz-García, Sohei Satoi, Marta Scorsetti, Martin Schneider, Thomas Seufferlein, Alejandro Serrablo, Shailesh V Shrikhande, Elizabeth C Smyth, Magali Svrcek, Kyoichi Takaori, Margaret A Tempero, Natalia S Tissera, Jeanne Tie, Orlando J M Torres, Anthony Turpin, Eric Van Cutsem, Eva Versteijne, Caterina Vivaldi, Zev A Wainberg, Ralph R Weichselbaum, Juergen Weitz, Christopher L Wolfgang, Gerald W Prager, Oliver Strobel Lancet Oncology, 2026
High-grade gliomas and Lynch syndrome: A retrospective descriptive study with a literature review Hugo Duprez, Apolline Monfilliette, Marie Csanyi, Claude-Alain Maurage, Fabienne Escande, Afane Brahimi, Anthony Turpin, Nicolas Reyns, Luc Defebvre, Enora Vauleon Neuro Oncology Practice, 2026 Background High-grade diffuse gliomas in adults are common malignant primary tumors of the central nervous system. The association with Lynch syndrome (LS) is documented but remains under-researched. However, there are implications for prevention, genetic counseling, and therapeutic approaches. The objective of this study is to conduct a descriptive cohort of patients with high-grade glial tumors in the context of LS. Methods We included adult patients with glioblastoma (GBM) or grade 4 astrocytoma (WHO 2021 classification) associated with LS, diagnosed at Lille University Hospital or Valenciennes Hospital between 2014 and 2022. We retrospectively collected clinical, radiological, histopathological, molecular, and therapeutic data. Results We included 6 GBM cases with a median age of 58.7 years (IQR 32.4-63.3). Five cases had MSH2 mutations, and one had PMS2 mutation. In one case, MMR protein expression was preserved, and the RER phenotype showed low microsatellite instability. Loss of ATRX expression, overexpression of p53, and giant cells were observed in 50%, 83%, and 66% of cases, respectively. TP53 mutations were found in all cases, and PTEN mutations in 4 cases. Immunotherapy was given to two cases. The 24-month overall survival rate was 50%. Conclusions GBMs associated with LS exhibit specific histopathological and molecular biology characteristics that may guide syndrome-related research. These tumors could represent a particular subclassification, potentially leading to specific therapies such as immunotherapy. We propose with a review of case in the literature an algorithm for investigating LS upon discovering a GBM. These exploratory results need to be confirmed by a larger cohort.
Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer Gael Roth, Pascal Artru, Olivier Bouche, Nicolas Williet, Julien Ghelfi, Anthony Turpin, Astrid Lievre, Jean-Frédéric Blanc, Camille Evrard, Jean-Baptiste Bachet, Pauline Parent, Marc Manceau, Matthieu Roustit, Anna Borowik, Victoire Granger, Aurélie Durand, Christelle d’Engremont, Edouard Girard, Mircea Chirica, Nicolas Braissand, Nicolas Rama, Eugénie Modolo, Hector Hernandez-Vargas, Elise Georges, Jean-Yves Scoazec, Jerome Cros, Sébastien Hazard, Benjamin Ducarouge, Thomas Decaens, Agnès Bernet, Patrick Mehlen Nature, 2026 Netrin1, a developmental cue, is a master regulator of tumour epithelial-to-mesenchymal transition (EMT)1, a mechanism that is known to drive resistance to chemotherapy2. A netrin1 antibody (NP137)3 has been shown to inhibit tumour EMT in preclinical1 and clinical4 settings. In animal models of pancreatic cancer, netrin1 and its receptor neogenin have been shown to promote tumour progression5, EMT5 and metastasis6. Here we report the results of a phase 1b study that assesses the combination of NP137 with modified FOLFIRINOX (mFOLFIRINOX) in first line patients with locally advanced pancreatic cancer (ClinicalTrials.gov: NCT05546853 ). Forty-three patients were enrolled and received mFOLFIRINOX plus NP137 every other week for up to 12 cycles. NP137 was well tolerated. Median progression-free survival (PFS) was 10.85 months (95% confidence interval, 10.03–15.61) and median overall survival was 16.43 months (95% confidence interval, 12.75–non-reached), with 21 patients remaining alive at the time of data cut-off. Post-therapy conversion surgery occurred in 23% of patients. Laser capture microdissection was performed on pre-therapeutic biopsies and surgical specimens. Microbulk RNA sequencing confirmed that the main pathway that was down-regulated with the combination of mFOLFIRINOX plus NP137 was EMT. Moreover, survival outcomes were extended for patients with tumour cells that expressed high levels of the netrin1 receptor neogenin—median PFS 15.65 months in neogenin-high versus 10.22 months in neogenin low. Our results support the idea that netrin1 blockade alleviates resistance to chemotherapy by inhibiting EMT, particularly in neogenin-high pancreatic cancer. The Lap-NET1 phase 1b trial reports that combined netrin1 antibody (NP137) plus modified FOLFIRINOX therapy on patients with locally advanced pancreatic cancer was well tolerated and improved progression-free survival and overall survival via inhibition of epithelial–mesenchymal transition.
Cholangiocarcinoma 2026: status quo, unmet needs and priorities Jesus M. Banales, Pedro M. Rodrigues, Silvia Affò, Jesper B. Andersen, Patricia Aspichueta, Luke Boulter, John Bridgewater, Diego F. Calvisi, Andres Cardenas, Vincenzo Cardinale, Guido Carpino, Cédric Coulouarn, Cristina Dopazo, Julien Edeline, Luca Fabris, Trine Folseraas, Alejandro Forner, Benjamin Goeppert, Mathias Heikenwalder, Timothy J. Kendall, Shahid A. Khan, Heinz-Josef Klümpen, Bas Groot Koerkamp, Angela Lamarca, Stacie Lindsey, Ana Lleo, Tom Luedde, Rocio I. R. Macias, Helen Morement, Jean-Charles Nault, Paula Olaizola, Maria J. Perugorria, Chiara Raggi, Lorenza Rimassa, Anna Saborowski, Juan W. Valle, Mathew Vithayathil, Arndt Vogel, Chiara Braconi, , Abel Sanchez, Adelaida La Casta, Aldo J. Montano-Loza, Alessandra Elvevi, Alessandro Parisi, Alexander Link, Ana Landa-Magdalena, Andres Munoz, Anthony Turpin, Anu Ustav, Apinya Jusakul, Arun Valsan, Benjamin Dwyer, Bogdan S. Ungureanu, Bruno Sangro, Christoph Schramm, Cindy Neuzillet, Constantino Fondevila, David J. Pinato, David Malka, Domingo Balderramo, Elide Gutierrez, Elisa Lozano, Emmanuel Boleslawski, Enrique Carrera Estupinan, Ernesto Sparrelid, Eugenio Gaudio, Fatima Higuera De La Tijera, Flavio Rocha, Florence Troisfontaine, Francesca Ratti, Frank Lammert, Gianpaolo Vidili, Gonzalo Sapisochin, Gregory B. Lesinski, Gregory Gores, Hannes Jansson, Hassan Malik, Jan Philipp Jonas, Javier Diaz Ferrer, Javier Vaquero, Jens U. Marquardt, Joana Espírito Santo, Jorge Adeva, Joris Erdmann, Jose J. G. Marin, Juan Carlos Roa, Juli Busquets, Juozas Kupcinskas, Krzysztof Zieniewicz, Lara Heij, Laura Goff, Laura Izquierdo-Sanchez, Leonardo G. Da Fonseca, Luca Maroni, Luis Bujanda, Mairéad G. McNamara, Marco Carbone, Marco Marzioni, Marco Rengo, Maria Melanie Deutsch, Mariano Ponz, Mario Strazzabosco, Markus Peck-Radosavljevic, Massimiliano Cadamuro, Massimiliano Salati, Massimo Colombo, Matei Mandea, Matias A. Avila, Matthias Evert, Mina Komuta, Mitesh Borad, Mohamed Bouattour, Mohamed El-Kassas, Monica I. Meneses-Medina, Monica Niger, Monique Verstegen, Nabeel Bardeesy, Nilofer Azad, Olivier Detry, Olivier Scatton, P. Martin Padilla-Machaca, Pilar Acedo, Pim B. Olthof, Piotr Milkiewicz, Rachel Guest, Rachna Shroff, Robert Montal, Robin Kate Kelley, Ruidong Xue, Sergio Gradilone, Shishir K. Maithel, Silvestre Vicent, Siwanon Jirawatnotai, Stefano Caruso, Stephanie Roessler, Stephen L. Chan, Stephen P. Pereira, Teresa Macarulla, Thomas Gruenberger, Tian V. Tian, Tim F. Greten, Tudor Mocan, Tushar Patel, Umair Mahmood, Umberto Cillo, Vera Megdanova, Victor Lopez-Lopez Nature Reviews Gastroenterology and Hepatology, 2026
Early-onset colorectal cancer, a new public health issue Thierry Ponchon, Bertrand Brieau, Stanislas Chaussade, Myriam Grace, Anthony Turpin, Robert Benamouzig Hepato Gastro Et Oncologie Digestive, 2025 In most countries where it has been implemented, organized screening for colorectal cancer between the ages of 50 and 74, along with early treatment of precancerous lesions, has made it possible over the years to significantly reduce the incidence and mortality of this cancer. However, since the early 2000s, epidemiological studies have reported a rise in the incidence and mortality of early-onset colorectal cancer (diagnosed before the age of 50) worldwide, in Europe, and in France. This increase has raised worldwide concern about the public health impact of early-onset colorectal cancer. Some countries have already decided to implement organized screening from the age of 45, or are actively considering it. In France, the increase in incidence and mortality could accelerate in the coming years, underscoring the need to take immediate action and strengthen prevention and screening for early-onset colorectal cancer. The question of lowering the recommended starting age for screening also requires careful consideration and preliminary studies.
Young-onset biliary tract cancers: Characteristics, treatment patterns, and patient outcomes Thomas Pudlarz, Anthony Turpin, Natalia Soledad Tissera, Marc Hilmi, Leony Antoun, Florian Castet, Daniel Lopez-Valbuena, Adrien Rousseau, Matthieu Delaye, Maximiliano Gelli, Antoine Italiano, Marine Valéry, Anthony Tarabay, Valérie Boige, David Malka, Eduardo García-Galea, Gloria Castillo, Tian V. Tian, Antoine Hollebecque, Cristina Smolenschi, Michel Ducreux, Teresa Macarulla, Alice Boilève Jhep Reports, 2025 Background & Aims: The incidence of biliary tract cancers (BTC) among young individuals (≤50 years) is currently rising. We aimed to investigate the clinical, therapeutic and molecular characteristics and outcomes of young-onset BTC (YO-BTC). Methods: ., the ratio of progression-free survival (PFS) with the targeted therapy line to the PFS of the n-1 line. Results: = 0.044), although no differences in PFS or OS were observed. Conclusion: fusions, highlighting opportunities for precision oncology-based approaches. Impact and implications: fusions. Physicians can apply these results by incorporating molecular profiling and targeted therapies earlier in the treatment plan for younger patients, potentially improving their prognosis and quality of life. However, it is crucial to consider the study's limitations, such as the retrospective design and potential selection bias, to avoid overgeneralization and ensure appropriate application of the findings in clinical practice and future research.
Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi) Marine Valery, Julien Edeline, Julie Henriques, Leony Antoun, Heloise Bourien, Antoine Lebeaud, Nadim Fares, Christophe Tournigand, Thierry Lecomte, David Tougeron, Vincent Hautefeuille, Angelique Vienot, Nicolas Williet, Jean-Baptiste Bachet, David Malka, Cristina Smolenschi, Antoine Hollebecque, Jane-Rose Paccard, Maxime Frélaut, Pascal Hammel, Anthony Turpin, Alice Boileve Therapeutic Advances in Medical Oncology, 2025
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative J. Taieb, J. Seligmann, D. Modest, C. Girault, F. Rivera, E. Mahillo, P. Osterlund, P. Pfeiffer, D. Malka, C. Louvet, A.R. Siebenhuner, C. Morf, C. de la Fouchardiere, L. Monard, M. Koopman, G. Vink, I. Borbath, L. Dewever, R. Adams, A. Reinacher-Schick, F. Pietrantonio, S. Lonardi, T. Aparicio, C. Cremolini, Pierre Laurent-Puig, David Tougeron, Côme Lepage, Aziz Zaanan, Jean Marc Phelip, Laetitia Dahan, Claire Gallois, Rosine Guimbaud, Véronique Vendrely, Christopher Jones, Christopher Williams, David Cairns, Nancy Fernandes Desilva, Karen Geboes, Sabine Tejpar, Veerle Casneuf, Leen Mortier, Jeroen Dekervel, Timon Vandamme, Anne Demols, Geneviève Van Ooteghem, Sofie Demeulder, Michèle Van Hooren, Francesco Sclafani, Marc Peeters, Jean-Louis Van Laethem, Marc Vanden Eynde, Eric Van Cutsem, Alain Hendlisz, Laura Delliponti, Federica Palermo, Lisa Salvatore, Monica Niger, Matteo Fassan, Lorenzo Fornaro, Massimo Di Maio, Florian Lordick, Dirk Arnold, Gunnar Folprecht, Arndt Vogel, Lukas Perkhofer, Alexander Stein, Peter Thuss-Patience, Volker Kunzmann, Thomas Ettrich, Annabel Alig, Ralf Hofheinz, Pompiliu Piso, Emmanouil Fokas, Enrique Aranda, Ana Fernandez Montes, Ramon Salazar, Elena Élez, Clara Montagut, Ángela Lamarca, Teresa Macarulla, Ruth Vera, Christophe Borg, Romain Cohen, Antony Turpin, Thierry Andre, Jean Baptiste Bachet, Pia Osterlund, Per Pfeiffer, Karen-Lise Garm Spindler, Tormod Guren, Marianne Guren, Christina Aasebo Overas, Julia Johansen, Inna Chen, Eetu Heervää, Bengt Glimelius, Arne Westgaar, Annika Ålgar, Benny Vittrup, Camilla Qvortrup, David Ljungman, Elin Kure, Bengt Gustafsson, Ellinor Bexe-Lindskog, Eva Serup Hansen, Eva Angenete, Gabor Istvan Liposits, Halfdan Sorbye, Helga Hagman, Inga Marie Loees, Jakob Eberhard, Jakob Hagen Vasehus Schou, Jan-Erik Frödin, Johan Haux, Kjell-Magne Tveit, Anders Jakobsen, Olav Dahl, Kjerstin Elvestaf Hestun, Line Tarpgaard, Mia Johansson, Niels Pallisgard, Pernille Holck Skov, Peter Nygren, Morten Braendengen, Ragnhild Loethe, Stine Winther, Svein Dueland, Torben Hansen, Sofia Heyman, Yvonne Wettergren, Emerik Osterlund, Oddmund Noordgard, Mats Perman, Jennie Aust, Sheraz Yaqub, Julian Hjamford, Jorgen Smeby, Kristoffer Lassen, Laurids Ostergard Poulsen, Maria Thomsen, Olav F. Dajani, Bard Rosok, Kristoffer Lassen, Kjetil Soreide, Anne Hansen Ree, Dieter Koberle, Thibaud Kossler, Sara De Dosso, Jeanine Roodhart, Miriam Chalabi, Remond Fijneman, Henk Verheul, Anna Tetering, Julien Edeline, Aurélien Lambert, Emmanuelle Samalin, Valérie Boige, Beata Juzyna ESMO Open, 2025
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer Julien Hoba, Adrien Grancher, Vincent Hautefeuille, Anthony Turpin, Karine Bouhier-Leporrier, Marie-Pierre Galais, Anne-Laure Bignon, Aude Di Fiore, Romain Desgrippes, Laurent Miglianico, Benoit Avisse, Mathieu Baconnier, You-Heng Lam, Marie Dutherage, David Sefrioui, Karine Le Malicot, Jean-Marc Phelip, Pierre Michel, André Gillibert, Frédéric Di Fiore Digestive and Liver Disease, 2025
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study Victoire Dabout, Laurent Mineur, David Tougeron, Karine Le Malicot, Claire Gallois, Jean Marc Phelip, Anthony Turpin, Romain Cohen, Benedicte Demoustier, Vincent Hautefeuille, Christophe Locher, Charles-Briac Levaché, Emmanuel Mitry, Thierry Lecomte, Fabien Brocard, Deborah Hassid, Marie Porte, Gilles Breysacher, Jean-Paul Lagasse, Côme Lepage, Marine Valéry, Jean-Baptiste Bachet Clinics and Research in Hepatology and Gastroenterology, 2025
Post-operative oligometastatic recurrence Anthony Turpin, Sara El Kurdi, Pauline Parent, Victoria Pacquement, Stéphanie Truant, Pascal Hammel Hepato Gastro Et Oncologie Digestive, 2024
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer Emeric Boisteau, Laetitia Dahan, Nicolas Williet, Karine Le Malicot, Jérôme Desramé, Olivier Bouché, Caroline Petorin, David Malka, Christine Rebischung, Thomas Aparicio, Cédric Lecaille, Yves Rinaldi, Anthony Turpin, Anne-Laure Bignon, Jean-Baptiste Bachet, Côme Lepage, Victoire Granger, Jean-Louis Legoux, Gaël Deplanque, Mathieu Baconnier, Thierry Lecomte, Isabelle Bonnet, Jean-François Seitz, Eric François, Astrid Lièvre, , Anna Pigui, Anne Escande, Denis Pezet, Muriel Duluc, Nicolas Barriere, Isabelle Moullet, Franck Audemar, Vincent Bourgeois, Agnès Vimal-Baguet, Emmanuelle Norguet, Jean-Paul Lagasse, Jean-Christophe Duchmann, Marielle Guillet, Stéphane Berdah, Robert Sverdlin, Julien Taieb, Stéphane Corbinais, Gérard Lledo, Laurent Bedenne, Mohamed Hebbar, Karine Bouhier-Leporrier, Charles Ferte, Lionel Staudacher, Ludovic Evesque, Stéphane Remy, Thierry Charlois, Catherine Lombard-Bohas, Aziz Zaanan, Corina Cornila, Antoine Hollebecque, Pascal Artru, Laure Dupont Kazma, Thomas Walter, Iris Devaure, Julie Gigout, Desauw, Anne Guilngar, Christophe Locher, Joël Ezenfis, Belletier, Valérie Boige, Stéphane Cattan, Caroline Coufon, Camille Sibertin-Blanc, Anne-Laure Villing, Pascal Burtin, Boulat, Pierre Andrau, Jérôme Meunier, Le Foll, Michel Ducreux, Laurianne Plastaras, Gilles Breysacher, Philippe Bernard, Aurelie Durand, Olivier Romano, Delphine Farneti, Mireille Simon, Marie Talarmin, Anne-Claire Dupont Gossart, Samuel Le Sourd, Fayçal Hocine, David Sefrioui, Florence Le Roy, Romain Desgrippes, Amalia Topolski, Florence Mary, Pierre Michel, Thomas Aparicio, Gérard Cavaglione, Nabil Baba-Hamed, Philippe Follana, Isabelle Cumin, Laurence Thomas Marques, Nathalie Baize, Nicolae Arsenii, Tatiana Ceban, Jean-Louis Jouve, Yann Molin, Marc Pracht Oncologist, 2024
Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort Antoine Lebeaud, Leony Antoun, Jane‐Rose Paccard, Julien Edeline, Hélène Bourien, Nadim Fares, Christophe Tournigand, Thierry Lecomte, David Tougeron, Vincent Hautefeuille, Angélique Viénot, Julie Henriques, Nicolas Williet, Jean‐Baptiste Bachet, Cristina Smolenschi, Antoine Hollebecque, Teresa Macarulla, Florian Castet, David Malka, Cindy Neuzillet, Dewi Vernerey, Alice Boilève, Anthony Turpin Liver International, 2024
International Expert Consensus on Semantics of Multimodal Esophageal Cancer Treatment: Delphi Study Charlène J. van der Zijden, Sjoerd M. Lagarde, Bianca Mostert, Joost J. M. E. Nuyttens, Manon C. W. Spaander, Bas P. L. Wijnhoven, Johanna W. van Sandick, Jolanda M. van Dieren, Francine E. M. Voncken, Jean-Pierre E. N. Pierie, Willem E. Fiets, Camiel Rosman, Peter D. Siersema, Heidi Rütten, Grard A. P. Nieuwenhuijzen, Geert-Jan Creemers, Erik J. Schoon, Maurice J. C. van der Sangen, Arjan Verschoor, Rutger Quispel, Meindert N. Sosef, Jeroen Buijsen, Hendrik H. Hartgrink, Marije Slingerland, Joos Heisterkamp, Laurens V. Beerepoot, Wouter L. Hazen, Tom Rozema, Karin Muller, Ewout A. Kouwenhoven, Simon Y. Law, Wendy W. Chan, Ian Y. Wong, Zhigang Li, Yin-Kai Chao, I-Chen Wu, Chiao-En Wu, Wing-Keen Yap, Seong Yong Park, Hiroya Takeuchi, Eisuke Booka, Ken Kato, Ito Yoshinori, Steven H. Lin, Guillaume Piessen, Anthony Turpin, Alexandre Taillez, Carlo Castoro, Alessandro Bastoni, Roberta Maselli, Marta Scorsetti, Thomas N. Walsh, Liam Grogan, , and Annals of Surgical Oncology, 2024
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability Mathilde Moreau, Emily Alouani, Clémence Flecchia, Antoine Falcoz, Claire Gallois, Edouard Auclin, Thierry André, Romain Cohen, Antoine Hollebecque, Anthony Turpin, Simon Pernot, Thérèse Masson, Frederic Di Fiore, Marie Dutherge, Thibault Mazard, Vincent Hautefeuille, Jean-Luc Van Laethem, Christelle De la Fouchardière, Géraldine Perkins, Meher Ben-Abdelghani, Francesco Sclafani, Thomas Aparicio, Stefano Kim, Dewi Vernerey, Julien Taieb, Rosine Guimbaud, David Tougeron European Journal of Cancer, 2024
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT) Gael S. Roth, Loic Verlingue, Matthieu Sarabi, Jean-Frédéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain, Julien Edeline, Maximiliano Gelli, Boris Guiu, Samy Horn, Valérie Laurent-Croise, Côme Lepage, Astrid Lièvre, Anthony Lopez, Sylvain Manfredi, Julie Meilleroux, Cindy Neuzillet, Valérie Paradis, Frédéric Prat, Maxime Ronot, Olivier Rosmorduc, Antonio Sa Cunha, Olivier Soubrane, Anthony Turpin, Christophe Louvet, Olivier Bouché, David Malka European Journal of Cancer, 2024
Preserving bone in cancers of the elderly: A necessity Nicolas Bertrand, Marie Bridoux, Cédric Gaxatte, Henry Abi Rached, Anthony Turpin, Jean-Guillaume Letarouilly, Marie-Hélène Vieillard Revue Du Rhumatisme Edition Francaise, 2024
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, Antoine Hollebecque, Jean Frederic Blanc, Mohamed Bouattour, Eric Assenat, Meher Ben Abdelghani, Matthieu Sarabi, Monica Niger, Caterina Vivaldi, Mario Mandalà, Andrea Palloni, Maria Bensi, Silvio Ken Garattini, David Tougeron, Pierre Combe, Massimiliano Salati, Margherita Rimini, Chiara Alessandra Cella, Marco Tucci, Anna Diana, Elena Mori, Raffaella Longarini, Pascal Artru, Gael Roth, Ludovic Evesque, Agathe Vienne, Anthony Turpin, Sandrine Hiret, Vincent Bourgeois, Camille Herve, Rodolphe Paulon, Marion Stacoffe, David Malka, Cindy Neuzillet, Julien Edeline, Astrid Lievre, Rosine Guimbaud, Marie Christelle Pajiep Chapda, Lorenza Rimassa, Riccardo Giampieri, Juan Valle, Rossana Berardi, Nadim Fares European Journal of Cancer, 2024
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study Clémence Flecchia, Edouard Auclin, Emily Alouani, Mathilde Mercier, Antoine Hollebecque, Anthony Turpin, Thibault Mazard, Simon Pernot, Marie Dutherage, Romain Cohen, Christophe Borg, Vincent Hautefeuille, Francesco Sclafani, Meher Ben-Abdelghani, Thomas Aparicio, Christelle De La Fouchardière, Camille Herve, Geraldine Perkins, Kathrin Heinrich, Volker Kunzmann, Claire Gallois, Rosine Guimbaud, David Tougeron, Julien Taieb British Journal of Cancer, 2024
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor Anthony Turpin, Carine Delliaux, Pauline Parent, Hortense Chevalier, Carmen Escudero-Iriarte, Franck Bonardi, Nathalie Vanpouille, Anne Flourens, Jessica Querol, Aurélien Carnot, Xavier Leroy, Nicolás Herranz, Tristan Lanel, Arnauld Villers, Jonathan Olivier, Hélène Touzet, Yvan de Launoit, Tian V. Tian, Martine Duterque-Coquillaud British Journal of Cancer, 2023
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study Marie Auvray Kuentz, Vincent Hautefeuille, Louis de Mestier, Clélia Coutzac, Thierry Lecomte, Victor Nardon, Pascal Artru, Anthony Turpin, Antoine Drouillard, David Malka, My‐Linh Tran‐Minh, Isabelle Trouilloud, Astrid Lièvre, Nicolas Williet, Simon Pernot, Yann Touchefeu, Julien Taieb, Pascal Hammel, Aziz Zaanan International Journal of Cancer, 2023
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard Epstein, Paul Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall Tebbutt, Gerald Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp-Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean-Luc Van Laethem, Stéphanie Laurent, Neesha Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke Parner, Tapio Salminen, Leena-Maija Soveri, Eija Korkeila, Pia Osterlund, Julien Taieb, David Tougeron, Pascal Artru, François Xavier Caroli-Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus-Alexander Wörns, Holger Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balazs Juhasz, László Landherr, Tamas Pinter, György Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek Power, Luca Gianni, Salvatore Siena, Michele Milella, Alfredo Falcone, Rossana Berardi, Cinzia Bagalà, Francesco Di Costanzo, Fausto Roila, Andrea Ardizzoni, Evaristo Maiello, Silvia Fanello, Johanna Wilmink, Jan Willem de Groot, Geert Creemers, Eduardo Barroso, Tânia Rodrigues, Cristina Sarmento, Cheng Ean Chee, David Tai, Teresa Macarulla Mercade, Manuel Hidalgo Medina, Alfredo Carrato Mena, Joan Maurel Santasusana, Maria Jose Flor Oncala, Carlos Gomez Martin, Rafael Lopez, Andres Muñoz, Ruth Vera Garcia, Inmaculada Ales, Berta Laquente Sáez, Fernando Rivera, Javier Sastre, Cheng-Chung Wu, Yu-Wen Tien, De-Chuan Chan, Tsann-Long Hwang, Jeffry Evans, Jonathan Wadsley, Pippa Corrie, Andrew Biankin, Andrew Ko, Dana Cardin, Elena Chiorean, Johanna Bendell, Anne Noonan, Hedy Kindler, Nishan Fernando, Muhammad Beg, Thomas George, Marcus Noel, Noelle LoConte, Francis Arena, James Posey, Rajat Malhotra, Charles Lopez, Davendra Sohal, Robert McWilliams, Warren Brenner, Mark Womack, Rahul Seth, Renuka lyer, Nathan Bahary, Robert Marsh, Robert Ramirez, Cynthia Chua, James Reeves, Gulam Manji, Anthony El-Khoueiry, Robert Weaver, Vaibhav Sahai, Wells Messersmith, Robert Dreicer, Ahmed Zakari, Andrea Bullock, Benjamin Musher, Mitesh Borad, Edward Kim, David Bajor, Tim Huyck, Hassan Hatoum, Henry Xiong, Boris Pasche, Jill Lacy, Olugbenga Olowokure, Allen Cohn, Donald Richards, Robert Martin, Andrew Paulson, Paul Fanta, Smitha Krishnamurthi, Paul Oberstein, Jyotsna Fuloria Journal of Clinical Oncology, 2023
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial Thomas Aparicio, Olivier Bouché, Pierre-Luc Etienne, Emilie Barbier, Laurent Mineur, Romain Desgrippes, Véronique Guérin-Meyer, Fayçal Hocine, Jean Martin, Valérie Le Brun-Ly, Jacques Cretin, Jérôme Desramé, Yves Rinaldi, Laurent Cany, Claire Falandry, Leila Bengrine Lefevre, Miguelle Marous, Eric Terrebonne, Laurent Mosser, Justine Turpin, Anthony Turpin, Lucille Bauguion, Cynthia Reichling, Marc Van den Eynde, Elisabeth Carola, Sandrine Hiret Digestive and Liver Disease, 2023
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernadó-Morales, Noemí Haro, Francis J. Giles, Óscar J. Pozo, Josep M. Miquel, Paolo G. Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, Joaquín Arribas, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V. Tian Clinical Cancer Research, 2023
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study Cécile Torregrosa, Simon Pernot, Pauline Vaflard, Audrey Perret, Christophe Tournigand, Violaine Randrian, Solene Doat, Cindy Neuzillet, Valérie Moulin, Morgane Stouvenot, Gael Roth, Tiffany Darbas, Benjamin Auberger, Tiphaine Godet, Marion Jaffrelot, Aurélien Lambert, Olivier Dubreuil, Cassandre Gluszak, Alice Bernard‐Tessier, Anthony Turpin, Lola‐Jade Palmieri, Olivier Bouche, Gael Goujon, Thierry Lecomte, David Sefrioui, Christophe Locher, Lucien Grados, Pauline Gignoux, Stéphanie Trager, Elise Nassif, Angélique Saint, Pascal Hammel, Cédric Lecaille, Mathilde Bureau, Marine Perrier, Damien Botsen, Vincent Bourgeois, Julien Taieb, Edouard Auclin International Journal of Cancer, 2022
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial Thierry Conroy, Florence Castan, Anthony Lopez, Anthony Turpin, Meher Ben Abdelghani, Alice C. Wei, Emmanuel Mitry, James J. Biagi, Ludovic Evesque, Pascal Artru, Thierry Lecomte, Eric Assenat, Lucile Bauguion, Marc Ychou, Olivier Bouché, Laure Monard, Aurélien Lambert, Pascal Hammel, Canadian Cancer Trials Group, the Unicancer-GI–PRODIGE Group, Eric Francois, Jean-François Ramee, Hélène Castanie, Marc Pracht, François Ghiringhelli, Emmanuel Maillard, Caroline Couffon, Julien Volet, Vincent Bourgeois, Marion Chauvenet, Jean-Frédéric Blanc, Denis Péré-Vergé, Christelle De La Fouchardiere, Antoine Adenis, Farid El Hajbi, Jaafar Bennouna, Patrick Texereau, Roger Faroux, Laurent Miglianico, Christian Platini, Jean-Louis Legoux, François-Xavier Caroli-Bosc, Karine Bouhier-Leporrier, Alice Gagnaire, Victoire Granger, Valérie Lebrun-Ly, Rosine Guimbaud, Yann Touchefeu, Mohamed Gasmi, Frédéric Di Fiore, Jean François Seitz, Pierre-Luc Etienne, Catherine Ligeza Poisson, Yves Rinaldi, Nabil Baba-Hamed, Jean Baptiste Bachet, Thomas Aparicio, Laurence Chone, Marielle Guillet, Julien Forestier, Eric Terrebonne, Mohamed Hebbar, Gilles Breysacher, Thierry Andre, Faiza Khemissa-Akouz, Vincent Hautefeuille, Véronique Guerin-Meyer, Johannes Hartwig, Yves Becouarn, David Malka, Christophe Louvet, Jean-Luc Raoul, Laurent Cany, Beata Juzina, Claire Jouffroy, Sophie Gourgou, Mohammad Rassouli, Haji Chalchal, Daniel Renouf, Ralph Wong, Frederic Lemay, Francine Aubin, Felix Couture, Elaine Mc Whirter, Stephen Welch, Petr Kavan, Brian Findlay, Christine Cripps, Pablo Cano, Shahid Ahmed, Mohammed Harb, Bryn Pressnail, Scott Dowden, Chris O'Callaghan JAMA Oncology, 2022
Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients Lucie Gehenne, Sophie Lelorain, Clarisse Eveno, Guillaume Piessen, Christophe Mariette, Olivier Glehen, Xavier D’journo, Muriel Mathonnet, Nicolas Regenet, Bernard Meunier, Anne-Sophie Baudry, Véronique Christophe, The FREGAT Working Group, Antoine Adenis, Thomas Aparicio, Eric Assenat, Maximilien Barret, Leonor Benhaim, Céline Benoit, Damien Bergeat, Valérie Boige, Fréderic Borie, Olivier Bouche, Damien Bourriez, Pierre-Yves Brichon, Cécile Brigand, Nicolas Carrere, Pierre Cattan, Niki Christou, Benoit Coffin, Romain Cohen, Denis Collet, Thierry Conroy, Xavier Benoit D’journo, Laetitia Dahan, Sophie Deguelte, Fréderic Di Fiore, Bertrand Dousset, Antoine Drouillard, Frédéric Dumont, Farid Elhajbi, Clarisse Eveno, Jean Michel Fabre, Joseph Fabre, Johan Gagniere, Marie Pierre Galais, Adeline Germain, Sophie Geyl, Olivier Glehen, Diane Goere, Jean Marc Gornet, Victoire Granger, Caroline Gronnier, Rosine Guimbaud, Vincent Hautefeuille, Morgane Helyon, Jacques Jougon, Gilles Lebreton, Jérémie H Lefevre, Côme Lepage, Astrid Lievre, Frédéric Marchal, Pierre Mathieu, Muriel Mathonnet, Tamara Mathysiak, Bernard Meunier, Nicolas Michot, David Moszkowicz, Driffa Moussata, Simon Msika, Cindy Neuzillet, Medhi Ouaissi, Brice Paquette, François Paye, Christophe Penna, Guillaume Père, Marine Perrier, Frédérique Peschaud, Denis Pezet, Valérie Phoutthsang, Guillaume Piessen, Marc Pocard, Paul Rat, Nicolas Regenet, Jean Marc Regimbeau, Florence Renaud, Jean-Marc Sabate, Régis Souche, Eric Terrebonne, Williams Tessier, Pascal Alexandre Thomas, Anthony Turpin, Delphine Vaudoyer, Angélique Vienot, Thibault Voron, Benoit You Supportive Care in Cancer, 2021
Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study Anthony Turpin, Thierry de Baere, Alexandra Heurgué, Karine Le Malicot, Isabelle Ollivier-Hourmand, Thierry Lecomte, Hervé Perrier, Julien Vergniol, David Sefrioui, Yves Rinaldi, Julien Edeline, Jean-Louis Jouve, Christine Silvain, Yves Becouarn, Barbara Dauvois, Mathieu Baconnier, Maryline Debette-Gratien, Gael Deplanque, Sébastien Dharancy, Côme Lepage, Mohamed Hebbar Clinics and Research in Hepatology and Gastroenterology, 2021
Two cases of immune thrombocytopenia associated with pembrolizumab Audrey Le Roy, Emmanuelle Kempf, Felix Ackermann, Emilie Routier, Caroline Robert, Anthony Turpin, Aurélien Marabelle, Christine Mateus, Jean-Marie Michot, Olivier Lambotte European Journal of Cancer, 2016
